Quadrivalent Human Papillomavirus (HPV) types 6, 11, 16, 18 vaccine: For the prevention of genital warts in males

Drugs

Volumn 71, Issue 5, 2011, Pages 591-602

  Garnock Jones, Karly P ^a   Giuliano, Anna R ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Adis Drug Profiles; Genital warts; Human papillomavirus infections; Human papillomavirus vaccine recombinant quadrivalent

Indexed keywords

AMORPHOUS ALUMINUM HYDROXYPHOSPHATE SULFATE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; SULFATE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

APPENDICITIS; ARTICLE; ASTHMA; BRONCHOSPASM; CONDOM; CONDYLOMA ACUMINATUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE JOINT MOVEMENT IMPAIRMENT; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; PELVIC INFLAMMATORY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRESCRIPTION; PROPHYLAXIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SEXUAL ORIENTATION; SEXUALLY TRANSMITTED DISEASE; SYNCOPE; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE;

EID: 79953249885     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205980-000000000-00000     Document Type: Article

References (36)

1. Hutchinson DJ, Klein KC. Human papillomavirus disease and vaccines. Am J Health Syst Pharm 2008 Nov 15; 65 (22): 2105-12.
2. Hsueh PR. Human papillomavirus, genital warts, and vaccines. J Microbiol Immunol Infect 2009 Apr; 42 (2): 101-6.
3. Giuliano AR, Salmon D. The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: point. Cancer Epidemiol Biomarkers Prev 2008; 17 (4): 805-9. (Pubitemid 351536409)
4. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epi- demiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 Suppl. 10: K17-28.
5. Miralles-Guri C, Bruni L, Cubilla AL, et al. Human pap- illomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009 Oct; 62 (10): 870-8.
6. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009; 36 (6): 380-6.
7. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 Aug; 24 Suppl. 3: S35-41. (Pubitemid 44293033)
8. Hillemanns P, Breugelmans JG, Gieseking F, et al. Estima- tion of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis 2008; 8: 76.
9. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009 Aug; 36 (8): 515-21.
10. Merck and Co. Gardasil® (human papillomavirus quad- rivalent [types 6, 11, 16, and 18] vaccine, recombinant, intramuscular injection): US prescribing information [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/g/gardasil/gardasil-pi.pdf [Accessed 2010 May 28].
11. Palefsky JM. Human papillomavirus-related disease in men: not just a women's issue [published erratum appears in J Adolesc Health 2010; 46: 614]. J Adolesc Health 2010; 46 Suppl. 4: S12-9.
12. Australian Government DoHaATGA. Human papilloma- virus vaccine (GARDASIL) [online]. Available from URL: http://www.tga.gov.au/alerts/medicines/gardasil. htm [Accessed 2010 Jun 28].
13. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769.
14. Smith MA, Canfell K, Brotherton JML, et al. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008; 123 (8): 1854-63.
15. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009 Dec; 85 (7): 499-502.
16. Heiligenberg M, Michael KM, Kramer MA, et al. Sero- prevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex Transm Dis 2010 Aug 19; 37 (11): 672-80.
17. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters 2008 Nov; 16 (32): 97-103.
18. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884.
19. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010 Oct; 28 (42): 6858-67.
20. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010 Dec; 10 (12): 845-52.
21. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov; 118 (5): 2135-45. (Pubitemid 46393698)
22. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human pap-illomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007 Mar; 26 (3): 201-9. (Pubitemid 46340765)
23. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011 Feb; 354 (5): 401-411.
24. Plus supplementary material available from URL: http://www.nejm.org [Accessed 2011 Feb 4].
25. Levin MJ, Moscicki A-B, Song L-Y, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55 (2): 197-204.
26. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papilloma-virus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010 Apr; 29 (4): 314-8.
27. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tol- erability, and immunogenicity of gardasil given concom-itantly with Menactra and Adacel. Pediatrics 2010; 125 (6): 1142-51.
28. Arguedas A, Soley C, Loaiza C, et al. Safety and immuno- genicity of one dose of MenACWY-CRM, an investiga-tional quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28 (18): 3171-9.
29. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008 Jan 30; 26 (5): 686-96.
30. US FDA. Clinical review of biologics license application supplement STN# 125126/1297.0: male indication for GARDASIL [online]. Available from URL: http://www. fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Ap provedProducts/UCM190977.pdf [Accessed 2010 Jun 1].
31. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007 Oct 15; 196 (8): 1153-62. (Pubitemid 47580270)
32. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus re-combinant vaccine. JAMA 2009 Aug 19; 302 (7): 750-7.
33. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human pap-illomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29 (2): 95-101.
34. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®. Vaccine. Epub 2010 May 6.
35. Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010 Jul; 28 (30): 4731-7.
36. Palefsky J. Vaccination; case studies; MSM [abstract no. CS 4-4]. EUROGIN 2010: annual meeting of the European Research Organisation on Genital Infection and Neoplasia; 2010 Feb 17-20; Monte Carlo